Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Revision History For: Arbutus Biopharma

22 Sep 2017 05:44 PM

08 Aug 2016 04:51 PM

03 Aug 2015 01:26 PM

27 Aug 2014 06:02 PM <--

28 Feb 2014 01:59 PM

Return to Arbutus Biopharma

Tekmira is a leader in the development of therapeutic agents based upon Nobel Prize winning breakthroughs in the field of gene silencing, known as RNA interference (RNAi). Tekmira's lead RNAi product candidates target cancer, Ebola infection, and other indications.

Read more about Tekmira's products here.